Comparative Pharmacology
Head-to-head clinical analysis: PERPHENAZINE versus THORAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERPHENAZINE versus THORAZINE.
PERPHENAZINE vs THORAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Perphenazine is a typical antipsychotic that exerts its effects by blocking postsynaptic dopamine D2 receptors in the brain, particularly in the mesolimbic pathway. It also has antagonistic activity at alpha-adrenergic, histaminergic, and muscarinic receptors.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
Oral: 4-16 mg 2-4 times daily; maximum 64 mg/day. Intramuscular: 5-10 mg every 6 hours; maximum 30 mg/day. Intravenous: 1-5 mg slow IV every 6 hours; maximum 10 mg/day.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
None Documented
None Documented
Clinical Note
moderatePerphenazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Perphenazine is combined with Fluticasone propionate."
Clinical Note
moderatePerphenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Perphenazine."
Clinical Note
moderatePerphenazine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Perphenazine."
Clinical Note
moderatePerphenazine + Methylphenidate
The terminal elimination half-life of perphenazine is approximately 8–12 hours in adults with normal hepatic function. This supports twice-daily dosing for maintenance therapy. In elderly patients or those with hepatic impairment, half-life may be prolonged.
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Perphenazine is extensively metabolized in the liver, primarily via CYP2D6, and eliminated predominantly as metabolites in urine (approximately 70%) and feces (about 30%). Less than 1% is excreted unchanged in urine.
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic
"The risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate."